<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512470312</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512470312</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Controversies in Multiple Sclerosis</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: No</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hillert</surname><given-names>Jan</given-names></name>
</contrib>
<aff id="aff1-1352458512470312">Department of Clinical Neuroscience, Karolinska Institutet and University Hospital, Stockholm, Sweden</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1352458512470312">Jan Hillert, Department of Clinical Neuroscience, Karolinska Institutet and University Hospital, Solna, Stockholm, SE-17176, Sweden. Email: <email>jan.hillert@ki.se</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>26</fpage>
<lpage>28</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<sec id="section1-1352458512470312">
<title>Rebuttal</title>
<p>Beta interferons (IFNb) and glatiramer acetate (GA) have played historic roles in transforming multiple sclerosis (MS) into a treatable disease, and remain the cornerstone in MS treatment even after 15 years. Whereas neither IFNb nor GA are far from perfect drugs in any of the three critical domains <italic>efficacy, tolerability</italic> or <italic>safety</italic>, they combine enough quality in each of these aspects to have remained attractive. As new treatments are introduced, it is inevitable that they will lose part of their markets. However, I predict that IFNb and GA should remain significant treatment alternatives for yet some years.</p>
<sec id="section2-1352458512470312">
<title>Efficacy</title>
<p>Ever since their introduction, IFNb and GA have been questioned for perceived feeble efficacy, usually expressed in terms of relapse rate (RR) reduction, usually around 30%. With a generation of newer drugs arriving with RR reductions of 53–68%, this is indeed IFNb’s and GA’s main weakness.<sup><xref ref-type="bibr" rid="bibr1-1352458512470312">1</xref><xref ref-type="bibr" rid="bibr2-1352458512470312"/>–<xref ref-type="bibr" rid="bibr3-1352458512470312">3</xref></sup> When comparing pivotal studies for other outcome measures, their inferiority is less obvious. Thus, in slowing of progression IFNb does relatively better, slowing short-term progression by up to 38%;<sup><xref ref-type="bibr" rid="bibr4-1352458512470312">4</xref>,<xref ref-type="bibr" rid="bibr5-1352458512470312">5</xref></sup> second-line treatments such as fingolimod (30%)<sup><xref ref-type="bibr" rid="bibr2-1352458512470312">2</xref></sup> and natalizumab (42%)<sup><xref ref-type="bibr" rid="bibr1-1352458512470312">1</xref></sup> are not much different. When assessing efficacy as a reduction of inflammation as visible on magnetic resonance imaging (MRI), differences are marginally larger. Thus, natalizumab reduces gadolinium-enhancing lesions by 92%<sup><xref ref-type="bibr" rid="bibr6-1352458512470312">6</xref></sup> and fingolimod by 82%;<sup><xref ref-type="bibr" rid="bibr2-1352458512470312">2</xref></sup> high-dose IFNb-1a reduces active lesions by 75–87%,<sup><xref ref-type="bibr" rid="bibr7-1352458512470312">7</xref></sup> whereas GA offers a 60% reduction.<sup><xref ref-type="bibr" rid="bibr8-1352458512470312">8</xref></sup> The corresponding figures for new or enhancing T2 lesions are 83% for natalizumab,<sup><xref ref-type="bibr" rid="bibr5-1352458512470312">5</xref></sup> 74% for fingolimod<sup><xref ref-type="bibr" rid="bibr2-1352458512470312">2</xref></sup> and 78% for IFNb,<sup><xref ref-type="bibr" rid="bibr6-1352458512470312">6</xref></sup> with GA trailing somewhat at 56%.<sup><xref ref-type="bibr" rid="bibr8-1352458512470312">8</xref></sup> The next likely newcomer, BG-12, performs similarly to natalizumab and fingolimod and reduces relapses by up to 53%, progression by 38%, enhancing lesions by 90% and T2 lesions by 85%.<sup><xref ref-type="bibr" rid="bibr3-1352458512470312">3</xref></sup></p>
<p>Admittedly, since patients in recent placebo-controlled pivotal studies have less active disease due to pre-existing treatments, comparisons of relative efficacy between studies can be questioned. However, head-to-head comparisons support the impression of similarity as outlined above. Direct comparisons of fingolimod with IFNb-1a and BG-12 with GA support the conclusion that the drugs BG-12 and fingolimod, perceived as more highly efficacious, outperform injectables on RRs but not on progression.<sup><xref ref-type="bibr" rid="bibr9-1352458512470312">9</xref>,<xref ref-type="bibr" rid="bibr10-1352458512470312">10</xref></sup> Given the established poor correlation of RR with long-term disability, IFNb, and possibly GA, may be less inferior to the emerging generation than commonly perceived.</p>
<p>Long-term efficacy of immunomodulation in MS remains a controversial topic since we lack a general methodology to compensate for lack of randomized controls. A number of studies have attempted to address this issue by comparing patients on treatment with controls selected to be as similar as possible, in principle by assigning propensity scores. Even so, results are inconsistent. A recent study by Shirani and co-workers failed to find any benefit for patients on treatment over 5 years compared with either historical or contemporary controls.<sup><xref ref-type="bibr" rid="bibr11-1352458512470312">11</xref></sup> However, Trojano and co-workers reported a striking benefit of IFNb in a propensity score-based analysis over 7 years.<sup><xref ref-type="bibr" rid="bibr12-1352458512470312">12</xref></sup> Most recently, Tedeholm and co-workers reported only half the risk of progressive disease when contemporary patients on treatment (IFNb and GA) were followed for up to 12 years and compared with matched historical controls.<sup><xref ref-type="bibr" rid="bibr13-1352458512470312">13</xref></sup> Clearly, propensity controlled studies critically depend on achieving full comparability and avoiding biases. Although long-term efficacy studies are in their infancy, the chances are that the efficacy of the first generation of MS disease modifiers has been underestimated.</p>
</sec>
<sec id="section3-1352458512470312">
<title>Mode of action</title>
<p>In recent years, a surprising number of novel studies of the pathophysiology of autoimmune diseases, including MS, have highlighted the importance of the interferon signalling pathway.<sup><xref ref-type="bibr" rid="bibr14-1352458512470312">14</xref></sup> Thus, a number of the recently discovered MS risk genes relate directly to interferon biology, for instance <italic>STAT3</italic> and <italic>IRF8</italic>.<sup><xref ref-type="bibr" rid="bibr14-1352458512470312">14</xref></sup> These admittedly circumstantial arguments suggest that IFNb exerts its effects via highly relevant cellular mechanisms, supporting its place in MS treatment.</p>
</sec>
<sec id="section4-1352458512470312">
<title>Tolerability</title>
<p>Even though the majority of patients historically offered IFNb and GA have been able to cope with the side effects and the inconvenience of needing to inject, the introduction of safe and efficacious oral therapies is likely to change patient perception of the tolerability of injectable treatment alternatives. Again, however, available evidence points to small differences in tolerability: in head-to-head comparisons, discontinuation on IFNb-1a i.m. or GA s.c. was no different to oral BG-12 and fingolimod.<sup><xref ref-type="bibr" rid="bibr9-1352458512470312">9</xref>,<xref ref-type="bibr" rid="bibr10-1352458512470312">10</xref></sup> Whether this translates into similar tolerability outside the format of a controlled trial remains to be seen.</p>
</sec>
<sec id="section5-1352458512470312">
<title>Safety</title>
<p>IFNb and GA are generally perceived as very safe drugs. In contrast, awareness of uncommon but severe adverse events of the second generation of MS treatments is high, even though experience is still limited for the latest arrivals. Thus, safety may prove the strongest argument for maintaining the traditional MS immunomodulators.</p>
</sec>
<sec id="section6-1352458512470312">
<title>May injectables be improved?</title>
<p>It is fair to state that even today’s most efficacious drugs leave an unmet efficacy need even in pre-progressive MS. For instance, even with natalizumab, less than 40% of patients are free from all signs of disease activity at 2 years.<sup><xref ref-type="bibr" rid="bibr15-1352458512470312">15</xref></sup> One may speculate that a satisfactory control of focal inflammation for many patients may require a combination of drugs with complementary modes of action. IFNbs and GA are evident candidates to be part of such treatment schemes, given their safety and tolerability.</p>
</sec>
<sec id="section7-1352458512470312">
<title>Conclusions</title>
<p>IFNb and GA have been shown to be inferior to the second-generation MS treatments mainly or only in reducing RR, a parameter questioned for its long-term relevance. Patient and neurologist preferences will determine whether the traditional injectables will remain useful. My guess is that a handful of efficacious, safe and tolerable first-line alternatives will be required to outcompete IFNb and GA. From an evidence point of view, there are good arguments to retain them as part of the treatment arsenal in MS for the foreseeable future.</p>
</sec></sec>
</body>
<back>
<ack>
<p>Critical comments on this paper from professors Sten Fredrikson and Fredrik Piehl are gratefully acknowledged.</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>Dr Hillert received honoraria for serving on advisory boards for BiogenIdec and Novartis and speaker’s fees from BiogenIdec, Merck-Serono, Bayer-Schering, Teva and Sanofi-Aventis. He has served as P.I. for projects sponsored by, or received unrestricted research support from, BiogenIdec, Merck-Serono, TEVA, Novartis and Bayer-Schering. His MS research is funded by the Swedish Research Council.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512470312">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>O’Connor</surname><given-names>P</given-names></name>
<name><surname>Havrdova</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source> <year>2006</year>; <volume>354</volume>: <fpage>899</fpage>–<lpage>910</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512470312">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kappos</surname><given-names>L</given-names></name>
<name><surname>Radue</surname><given-names>EW</given-names></name>
<name><surname>O’Connor</surname><given-names>P</given-names></name>
<etal/>
</person-group>.; <collab>FREEDOMS Study Group</collab>. <article-title>A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source> <year>2010</year>; <volume>362</volume>: <fpage>387</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512470312">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gold</surname><given-names>R</given-names></name>
<name><surname>Kappos</surname><given-names>L</given-names></name>
<name><surname>Arnold</surname><given-names>DL</given-names></name>
<etal/>
</person-group>.; <collab>DEFINE Study Investigators</collab>. <article-title>Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source> <year>2012</year>; <volume>367</volume>: <fpage>1098</fpage>–<lpage>1107</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512470312">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jacobs</surname><given-names>LD</given-names></name>
<name><surname>Cookfair</surname><given-names>DL</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
<etal/>
</person-group>.; <collab>The Multiple Sclerosis Collaborative Research Group (MSCRG)</collab>. <article-title>Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>1996</year>; <volume>39</volume>: <fpage>285</fpage>–<lpage>294</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512470312">
<label>5.</label>
<citation citation-type="journal">
<collab>PRISMS Study Group</collab>. <article-title>Randomised double-blind placebo-controlled study of interferon-1a in relapsing/remitting multiple sclerosis</article-title>. <source>Lancet</source> <year>1998</year>; <volume>352</volume>: <fpage>1498</fpage>–<lpage>1504</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512470312">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>DH</given-names></name>
<name><surname>Soon</surname><given-names>D</given-names></name>
<name><surname>Fernando</surname><given-names>KT</given-names></name>
<etal/>
</person-group>.; <collab>AFFIRM Investigators</collab>. <article-title>MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS</article-title>. <source>Neurology</source> <year>2007</year>; <volume>68</volume>: <fpage>1390</fpage>–<lpage>1401</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512470312">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>DK</given-names></name>
<name><surname>Paty</surname><given-names>DW</given-names></name>
</person-group> <article-title>Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis</article-title>. <source>Ann Neurol</source> <year>1999</year>; <volume>46</volume>: <fpage>197</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512470312">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Comi</surname><given-names>G</given-names></name>
<name><surname>Martinelli</surname><given-names>V</given-names></name>
<name><surname>Rodegher</surname><given-names>M</given-names></name>
<etal/>
</person-group>.; <article-title>PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source> <year>2009</year>; <volume>374</volume>: <fpage>1503</fpage>–<lpage>1511</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512470312">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JA</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<name><surname>Comi</surname><given-names>GC</given-names></name>
<etal/>
</person-group>. <article-title>Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source> <year>2010</year>; <volume>362</volume>: <fpage>402</fpage>–<lpage>415</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512470312">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fox</surname><given-names>R</given-names></name>
<name><surname>Miller</surname><given-names>DH</given-names></name>
<name><surname>Phillips</surname><given-names>JT</given-names></name>
<etal/>
</person-group>. <article-title>Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis</article-title>. <source>N Engl J Med</source> <year>2012</year>; <volume>367</volume>: <fpage>1087</fpage>–<lpage>1097</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512470312">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shirani</surname><given-names>A</given-names></name>
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<name><surname>Karim</surname><given-names>ME</given-names></name>
<etal/>
</person-group>. <article-title>Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis</article-title>. <source>JAMA</source> <year>2012</year>; <volume>308</volume>: <fpage>247</fpage>–<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512470312">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trojano</surname><given-names>M</given-names></name>
<name><surname>Pellegrini</surname><given-names>F</given-names></name>
<name><surname>Fuiani</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>New natural history of interferon-treated relapsing multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2007</year>; <volume>61</volume>: <fpage>300</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512470312">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tedeholm</surname><given-names>H</given-names></name>
<name><surname>Lycke</surname><given-names>J</given-names></name>
<name><surname>Skoog</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs</article-title>. <source>Mult Scler J</source> <year>2012</year>; <month>Nov</month> <day>1</day> (epub ahead of print).</citation>
</ref>
<ref id="bibr14-1352458512470312">
<label>14.</label>
<citation citation-type="journal">
<collab>International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2</collab>. <article-title>Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis</article-title>. <source>Nature</source> <year>2011</year>; <volume>476</volume>: <fpage>14</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr15-1352458512470312">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Havrdova</surname><given-names>E</given-names></name>
<name><surname>Galetta</surname><given-names>S</given-names></name>
<name><surname>Stefoski</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Freedom from disease activity in multiple sclerosis</article-title>. <source>Neurology</source> <year>2010</year>; <volume>74</volume>(<supplement>Suppl 3</supplement>): <fpage>S3</fpage>–<lpage>S7</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>